Skip to main content
Premium Trial:

Request an Annual Quote

Hannes Smarason Leaves Decode, Suzanne Mattingly Joins Exagen as VP of Business Development, Sally Brashears Becomes VP for IP at Benitec, and Others

Hannes Smarason will leave his post as executive vice president and senior business officer of Decode Genetics to focus on his duties as chairman of the board of Icelandair, Decode said last week. He will continue to consult for Decode, which is based in Reykjavik, Iceland.


Suzanne Mattingly has become vice president of business development and marketing of Exagen Diagnostics, the Albuquerque, NM-based company said on Monday. She joins the company from Fast Track Systems, where she was vice president for marketing. Mattingly holds a PhD in microbiology and virology from the Medical College of Virginia.


Sally Brashears has been appointed vice president for IP at Benitec, the Queensland, Australia-based company said last week. She recently worked as an outside US patent counsel to the National Stem Cell Center in Melbourne, Australia.


Further, Benitec has added Avocel co-founder Mark Kay, Jo Milner, and former Avocel SAB members Robert Lanford and David Russell to its scientific advisory board. Benitec acquired Avocel last month. Kay, who will be deputy chairman of the SAB, is a professor in the department of pediatrics and genetics at Stanford University School of Medicine. Milner is a professor of cell biology at the University of York in the UK, Lanford is a scientist at the Southwest Foundation for Biomedical Research in San Antonio, Texas, and Russell is an associate professor of medicine at the University of Washington in Seattle.


In addition, Benitec has created a clinical advisory committee for its Hepatitis C program, appointing Robert Carithers, director of the hepatology program at the University of Washington Medical Center in Seattle, Emmet Keeffe, chief of hepatology at Stanford University in Palo Alto, and Paul Pockros, divison head of gastroenterology/hepatology at Scripps Clinic in La Jolla, Calif.


Dawn Bordeaux has been promoted to vice president of regulatory affairs and quality assurance at Gentris, the Research Triangle Park-based company said last week. She used to be an executive director of quality assurance.


Jay Flatley and Jim Schlater have joined the board of directors of GenVault, the San Diego-based biosample management company said yesterday. Flatley is president and CEO of Illumina. Prior to that, he was president and CEO of Molecular Dynamics. Schlater is founder and chairman of the board of directors of Cell Biosciences. He is also a co-founder of Applied Biosystems, and he was the first president and CEO of Molecular Dynamics.


Alexander Cappellohas retired from the board of directors of CytRx "based on personal and family considerations," the Los Angeles-based RNAi company said on Monday

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.